CIRM Funded Clinical Trials

Selective, Off-the-Shelf Logic Gated CAR NK Cell Therapy Targeting CD33 and/or FLT3 Expressing Hematologic Malignancies

Disease Area:
Leukemia, Acute Myeloid (AML)
Investigator:
CIRM Grant:
CLIN2-16156 (Active)
Award Value:
$8,000,000.00
Trial Sponsor:
Senti Biosciences, Inc.
Trial Stage:
Phase 1
Trial Status:
Launching
Targeted Enrollment:
N/A

CIRM Clinical Trial Resources


Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox


Video on Stem Cell Trials


Other Resources

ISSCR Patient Website

ClinicalTrials.gov